|
|
||||||||
J Thorac Cardiovasc Surg 2000;119:305-313
© 2000 Mosby, Inc.
SURGERY FOR CONGENITAL HEART DISEASE |
-PHENYL-TERT-BUTYL NITRONE ATTENUATES THE CEREBRAL RESPONSE TO DEEP HYPOTHERMIC ISCHEMIA
From the Department of Pediatric Cardiac Surgery, Duke University Medical Center, Durham, NC.
Address for reprints: Stephen Langley, MD, Department of Cardiothoracic Surgery, Southampton General Hospital, Southampton, Hampshire, SO16 6YD, United Kingdom (E-mail: StephenLangley{at}dial.pipex.com) .
| Abstract |
|---|
|
|
|---|
-phenyl-tert -butyl nitrone, a free radical spin trap (PBN group; n = 6). All piglets underwent cardiopulmonary bypass, cooling to 18°C, 60 minutes of circulatory arrest followed by 60 minutes of reperfusion, and rewarming. Cerebral blood flow and metabolism were determined at baseline before deep hypothermic circulatory arrest and after 60 minutes of reperfusion.
-phenyl-tert -butyl nitrone before the arrest period attenuates the normal response to ischemia and improves recovery by affording protection from free radicalmediated damage. | Introduction |
|---|
|
|
|---|
The nitrones were developed in the 1960s specifically for the indirect detection of short-lived free radical species. One such nitrone is
-phenyl-tert -butyl nitrone, or PBN. Chemicals that can combine with free radicals to allow detection by electron spin resonance are known as "spin traps," and the combination of the free radical with the nitrone is termed a "spin adduct." PBN was first described in the context of free radical spin trapping in 1968.
1 Although nitrone spin traps have been used to detect free radicals since the 1960s, it was not until 20 years after this that consideration was given to their therapeutic potential. Neuroprotective properties of the nitrones were not described until the early 1990s.
2,3
At least three chemical species, superoxide (O2), hydrogen peroxide (H2O2), and hydroxyl (OH) free radicals, are involved in oxygen-derived free radical damage in biologic systems. Oxygen-derived free radicals play a key role in the pathologic processes induced by cerebral ischemia, and the OH radical is the most important of the oxygen-derived free radicals in this context. Ischemia-reperfusion injury induces OH radical formation in brain microvessels.
4 Subsequent free radical damage to the cerebral vasculature causes an increase in permeability of the blood-brain barrier,
5,6 altered membrane ion transport activity,
7 and enhanced neutrophil adhesion to the vascular endothelium.
8
In addition to cerebral vascular injury, oxygen-derived free radicals induce membrane lipid peroxidation.
9 Neuronal membranes are particularly susceptible to free radical attack because they are rich in polyunsaturated fatty acids. Potential consequences of damage to membrane lipid include changes in fluidity and permeability and in the orientation of proteins embedded in the bilayer of the plasma membrane and in other cellular endomembranes.
10 Other important targets for free radical attack are proteins, amino acids, nucleic acid bases, carbohydrates, neurotransmitters, and DNA.
11 The resulting alterations in morphology and function are potentially lethal, causing neuronal death. The enhanced propensity of cerebral tissue to peroxidize, the fact that it is intricately and highly organized and carries out central information processing, plus the fact that neurons are postmitotic cells combine to make free radical damage a particularly serious problem in the brain.
The generation of free radicals after cerebral ischemia would appear to be central to the subsequent vascular and neuronal damage. Scavenging of these free radicals could offer enormous therapeutic benefit. The aim of this study was to use PBN to indirectly assess the role of free radicals in the impairment of cerebral recovery that is known to follow a period of deep hypothermic circulatory arrest (DHCA) in children.
12 The null hypothesis is that free radicals are not involved in the post-DHCA impairment in cerebral blood flow (CBF) and cerebral metabolism (CMRO2) and that PBN given before cardiopulmonary bypass (CPB) will have no effect on cerebral recovery after 60 minutes of DHCA in the neonatal piglet.
| Material and methods |
|---|
|
|
|---|
Twelve neonatal piglets (1-2 weeks old) were anesthetized with an intramuscular injection of ketamine (50 mg · kg1) and acepromazine (15 µg · kg1). Intravenous methylprednisolone (30 mg · kg1) was administered via a 24-gauge cannula in the marginal vein of the pinna. Orotracheal intubation was performed and mechanical ventilation (Infant Ventilator, Sechrist Industries, Anaheim, Calif) was commenced to achieve arterial oxygen tensions of 150 to 250 mm Hg and carbon dioxide tensions of 35 to 45 mm Hg. The animals were paralyzed with intravenous pancuronium (300 µg · kg1) and anesthetized with fentanyl (100 µg · kg1). Thereafter, anesthesia was maintained with a continuous infusion of fentanyl (25 µg · kg1 · h1). An 18-gauge cannula was placed in the descending aorta via the femoral artery for blood pressure monitoring and arterial blood sampling. The animals temperature was monitored throughout the study by an indwelling nasopharyngeal temperature probe (Yellow Springs Instrument Co Inc, Yellow Springs, Ohio). Temperature was maintained at 36°C except for the period of induced hypothermia.
The heart was exposed through a median sternotomy. Cardiac instrumentation consisted of a 3F micromanometer (Millar Instruments, Inc, Houston, Tex) inserted into the superior vena cava for central venous pressure monitoring and placement of an 8-mm flow probe (Transonic Systems, Inc, Ithaca, NY) around the proximal pulmonary artery for cardiac output monitoring.
Sagittal sinus access.
The animals were anticoagulated with intravenous heparin (500 IU/kg) before access of the sagittal sinus. A 1-cm strip of scalp was raised in the midline over the vertex of the skull. Two separate 2-mm burr holes were made over the superior sagittal sinus for repeated sampling of sagittal sinus venous blood and continuous monitoring of sagittal sinus venous pressure with a 3F micromanometer (Millar Instruments).
CPB and circulatory arrest.
An 8F arterial cannula and a 20F venous cannula (DLP Inc, Grand Rapids, Mich) were inserted through purse-string sutures into the ascending aorta and the right atrium, respectively. CPB was commenced at a flow rate of 120 mL · kg1 · min1. The pump-oxygenator system consisted of a Sarns nonpulsatile roller pump (Sarns Inc/3M Health Care, Ann Arbor, Mich) and a Medtronic Minimax PLUS hollow-fiber membrane oxygenator (Medtronic Inc, Anaheim, Calif). No arterial filter was used. The circuit was primed with heparinized fresh blood from a donor pig. Ringers lactate and sodium bicarbonate solutions were added to the prime to achieve a hematocrit value of 0.25 and a pH of 7.4 at 37°C. The total prime volume was approximately 450 mL. The temperature of the perfusate was controlled with the integral heat exchanger in the venous reservoir of the oxygenator and a BIO-CAL 370 water bath system (Medtronic Bio-Medicus, Eden Prairie, Minn). Animals were cooled to a temperature of 18°C over a standard duration of 20 minutes by the circulation of ice water through the heat exchanger. At the end of the cooling period, the circulation was arrested and blood was drained from the animal. DHCA was therefore established and the aortic and right atrial cannulas were clamped. After 60 minutes of DHCA, the aortic and venous cannulas were unclamped. Perfusion was re-established at 120 mL · kg1 · min1 with the perfusate initially at room temperature (20°C-22°C). Rewarming was accomplished by circulating warm water through the heat exchanger in the venous reservoir. A nasopharyngeal temperature of 36°C was generally reached by 45 minutes of reperfusion. During cooling and rewarming, blood gases were managed according to the alpha-stat strategy. The arterial pH was maintained at 7.35 to 7.45 and carbon dioxide tension at 35 to 45 mm Hg, measured at 37°C and uncorrected for the temperature of the animal. Arterial oxygen tension was kept between 150 and 250 mm Hg and hematocrit between 0.23 and 0.28. Sodium bicarbonate (8.4%) was given when necessary but not immediately before CBF measurements. At the end of the study, the animals were killed by a bolus injection of fentanyl and cessation of CPB.
Measurement of CBF.
CBF measurements were determined by the reference-sample, radiolabeled microsphere technique
13 during CPB at 36°C. The technique described in the current study is the same as that used in previous reports from our laboratory.
14 Suspensions of microspheres with a diameter of 15.5 ± 0.1 µm (E.I. DuPont de Nemours & Company, Wilmington, Del) were made up in 10% dextran and 0.01% TWEEN 80 with 106 microspheres per milliliter. Two different isotopes were used in each piglet and these were chosen at random from the three different isotopes available (46Sc, 103Ru, and 95Nb). For each flow measurement, 106 microspheres were injected into a side port of the arterial tubing 30 cm proximal to the aortic cannula over 30 seconds and washed through with 5 mL of warm saline solution. A reference blood sample was withdrawn from the distal aorta at a constant rate of 3 mL · min1 with a Harvard syringe pump (Harvard Apparatus, South Natick, Mass) commencing 10 seconds before the microsphere injection and continuing for 2 minutes. At the end of the experiment, the brain was removed and divided into left and right cerebral hemispheres, basal ganglia, cerebellum, and brain stem (midbrain, pons, and medulla oblongata). In addition, the kidneys were also removed for determination of renal blood flow. After measurement of fresh weights, the brain parts and kidneys were dissolved in 2 mol/L potassium hydroxide solution and analyzed, together with the reference blood sample, in a gamma counter (Auto-Gamma 5530; Packard Instrument Co, Meriden, Conn) to estimate the quantity of each type of radiolabeled microsphere present in the specimen. The withdrawal rate of the reference blood sample and the ratio of counts from a brain part to the reference blood sample allowed calculation of regional CBF. CBF measurements are expressed in milliliters per 100 g of brain per minute by normalizing for fresh tissue weight. The weighted sum of regional CBF allowed calculation of global CBF.
Cerebral perfusion pressure (CPP) was taken as the difference between the mean arterial pressure and the sagittal sinus venous pressure. Cerebral vascular resistance (CVR) was the ratio of CPP to global CBF (in milligrams of mercury per 100 g per minute per milliliter). Systemic vascular resistance was taken as the ratio between the systemic perfusion pressure and the total bypass pump flow rate (systemic vascular resistance = [mean arterial pressure right atrial pressure]/ [pump flow rate] in millimeters of mercury per 100 g per minute per milliliter).
Measurement of cerebral oxygen handling.
Arterial and sagittal sinus blood samples were taken just before each microsphere injection for estimation of oxygen tension, carbon dioxide tension, oxygen saturation, pH, and base excess by means of a GEM-Stat blood gas/electrolyte monitor (Mallinckrodt Sensor Systems, Inc, Ann Arbor, Mich). Hemoglobin levels (in grams per deciliter) were measured from arterial blood samples (482 Co-Oximeter; Instrumenta-tion Laboratory Corp, Lexington, Mass). Cerebral delivery of oxygen (CDO2 in milliliters per 100 g brain per minute), cerebral metabolic rate of oxygen (CMRO2 in milliliters per 100 g brain per minute) and cerebral oxygen extraction (CEO2 as a percent) were calculated as follows:
CDO2 = CBF x arterial oxygen content
CMRO2 = CBF x (arterial oxygen content sagittal sinus venous oxygen content)
CEO2 = (CMRO2/CDO2) x 100%
The oxygen content (in milliliters of oxygen per milliliter of blood) was calculated by the following formula:
Oxygen content = 0.01 x [(1.36) (hemoglobin) (oxygen saturation) + (0.003) (oxygen tension)]
Experimental protocol and data collection.
The animals were randomized into 2 groups with 6 animals in each group. The study group received a PBN concentration of 100 mg · kg1 (Sigma Chemical Company, St Louis, Mo) in 5 mL of normal saline solution intravenously at induction plus an additional 200 mg · kg1 in 10 mL of normal saline solution in the pump. Control animals received 5 mL of normal saline solution intravenously at induction plus 10 mL in the pump. All animals were cannulated for CPB, and normothermic perfusion was commenced at 120 mL · kg1 · min1. The animals were stabilized on normothermic CPB for a minimum of 20 minutes before the pre-DHCA measurement was taken. During this time the pump flow was adjusted to provide a constant CPP of 50 mm Hg. After the pre-DHCA measurement, pump flow was returned to 120 mL · kg1 · min1 and the animals were cooled for DHCA. At the end of 60 minutes of DHCA, circulation was recommenced and the animals were rewarmed. At 45 minutes of reperfusion, pump flow rate was again adjusted to provide a CPP of 50 mm Hg for 15 minutes before the post-DHCA CBF measurement was made at 60 minutes of reperfusion. Data collected at the two time points included nasopharyngeal temperature, mean arterial blood pressure, right atrial pressure, sagittal sinus venous pressure, arterial and sagittal sinus blood gases, CPB flow rate, electrolytes, hematocrit, hemoglobin, CBF, and renal blood flow.
Statistical analysis.
All the results were entered into an Excel 97 spreadsheet (Microsoft Corporation, Redmond, Wash) for further analysis. Repeating formulas were set up to calculate the mean and standard error of the mean for all the data collected in each animal. Further repeating formulas were programmed for calculation of the CBF, CDO2, CEO2, CMRO2, and the percentage change between these, before and after DHCA, for all animals. A 2-tailed paired samples t test was used to compare means at different time points within a group. An unpaired (independent samples) t test was used to compare means between the groups. Statistical significance was tested at the 95% confidence limit.
| Results |
|---|
|
|
|---|
Effects of DHCA in the control group.
In the control group, after 1 hour of DHCA the systemic vascular resistance fell from 0.43 ± 0.03 mm Hg · 100 g · min · mL1 before DHCA to 0.35 ± 0.02 mm Hg · 100 g · min · mL1 after DHCA (P = .06). This fall necessitated a rise in mean pump flow from 137 ± 8 mL · kg1 · min1 before DHCA to 170 ± 10 mL · kg1 · min1 after DHCA (P = .04) to maintain the preset CPP of 50 mm Hg at the time of CBF measurement. CBF was significantly reduced to all regions of the brain after DHCA (P < .009) (Table I). Different brain regions were affected to varying degrees, with recovery of blood flow lowest in the cerebral hemispheres and greatest in the cerebellum (Fig 1).
|
|
|
|
|
Recovery of CBF after DHCA in the PBN group was significantly greater than in the control group globally and in all brain regions (P < .02) (Fig 1
). Recovery of flow to the cerebellum, brain stem, and basal ganglia occurred to such an extent that there was no significant difference between the regional blood flow determined before and after DHCA in these regions. Global cerebral oxygen handling in the PBN group is shown in Fig 4. After DHCA there was no significant change in global CDO2 (Table II
). Regional analysis determined that only in the cerebral hemispheres, where CDO2 fell from 5.8 ± 0.3 to 4.1 ± 0.4 mL · 100 g1 · min1, was there a significant difference in CDO2 before and after DHCA (P = .01). In all regions, the percentage recovery of CDO2 was significantly greater in the PBN group than in the control group (P < .01). After DHCA in the PBN group, recovery in CMRO2, both globally and in all regions, occurred to such an extent that no significant difference was detected between the pre-DHCA and post-DHCA values (P > .1). Regional recovery of the CMRO2 was significantly higher than in the control group in all brain regions (P < .04) (Fig 2
).
|
| Discussion |
|---|
|
|
|---|
In the current study, after 60 minutes of DHCA at 18°C and 60 minutes of rewarming in the control group, the systemic vascular resistance fell and the pump flow was therefore increased to maintain a constant CPP at the time of CBF measurement. The CVR rose after DHCA, resulting in a fall in CBF. Production of free radicals during reperfusion may be responsible for this reduction in CBF. Damage by oxygen-derived free radicals during cerebral reperfusion has previously been shown to be important in the etiology of reduced CBF (and CMRO2 abnormalities) after ischemia.
17 It is also of interest that the production of lipid peroxides, which are generated by free radical damage, after subarachnoid hemorrhage is thought to be responsible for the subsequent cerebral vasospasm seen in this condition.
18 As the arterial oxygen content was maintained at a constant level, the reduction in CBF was primarily responsible for the drop in CDO2 seen in all brain regions after DHCA. Oxygen extraction was increased and the combination of reduced CBF and increased CEO2 resulted in a fall in the CMRO2 in all regions. The finding of impaired CMRO2 is consistent with previous studies of normothermic global cerebral ischemia-reperfusion injury.
17
In the animals that received PBN, the systemic vascular resistance rose significantly after DHCA. The increase in systemic vascular resistance in the DHCA group compared with the control group suggests that in the control group the drop in resistance was due to systemic vasodilatory effects of free radicals. After DHCA the CBF was significantly greater in the PBN group than in the control group in all brain regions. This suggests that the reduction of CBF in the control group was due, at least in part, to an increase in free radical activity as a result of DHCA. Previous experimental evidence has shown that PBN results in improvement in CBF after cerebral ischemia-reperfusion injury.
19,20 A study by Inanami and Kuwabara
19 showed that PBN increased CBF in a dose-dependent manner. Furthermore, inhibition of nitric oxide synthase, an enzyme that produces nitric oxide, resulted in attenuation of the PBN effect. This suggests that the PBN-induced increase in CBF is strongly associated with nitric oxiderelated vasodilatation.
19 Schulz and associates
20 suggested that the vascular endothelium was a primary target for the damaging action of free radicals.
Recovery of CDO2 occurred to such an extent both globally and in all areas of the brain except the cerebral hemispheres that there was no significant difference before and after DHCA. This reflects the improvement in post-DHCA CBF with PBN. After DHCA there was no significant difference in CMRO2 compared with the pre-DHCA level. Therefore, when PBN is given before CPB, a normal cerebral metabolic recovery results after 60 minutes of DHCA. PBN results in a pronounced recovery of energy state after focal cerebral ischemia, with both adenosine triphosphate and lactate contents approaching normal.
21 The improvement in metabolic recovery with PBN is thought to be due to the effect of the spin trap at the mitochondrial level.
22
PBN improves the histologic and neurobehavioral recovery in both focal and global models of cerebral ischemia. The size of the infarct is reduced after both permanent and transient middle cerebral artery occlusion.
20,23 In addition, a reduction in cerebral edema, attenuation of neuronal damage in the CA1 area of the hippocampus, and improvement in neurologic behavior test results have been demonstrated with PBN after cerebral ischemic injury.
23-25 In one study a significant improvement in neurobehavioral score was seen even when PBN was given 12 hours after the ischemic episode.
23 In combination, these findings demonstrate that PBN has a strong neuroprotective effect and support the hypothesis that free radicals play an important role in brain injury after cerebral ischemia.
In addition to the beneficial effects of PBN that have been demonstrated in models of cerebral ischemia, its use has been shown to provide protection for other organs including the heart,
26,27 lungs,
28 and kidneys
29 in a variety of experimental models. In the current study, a significant improvement in renal blood flow was noted in the PBN group after DHCA. This effect has the potential to reduce renal morbidity after DHCA and could have important implications in pediatric cardiac surgical practice.
Free radicals are known to contribute to tissue injury in a wide variety of pathologic conditions including trauma, Parkinson disease, arthritis, carcinogenesis, ionizing radiation, ozone damage, and aging. In addition, there is now considerable evidence that oxygen-derived free radicals are responsible for cell damage in the course of cerebral ischemia. This study suggests that free radicals are involved in the impairment in cerebral recovery that follows a period of DHCA, and the null hypothesis stated previously can be rejected. The most likely mechanism of improved outcome after treatment with PBN in the current study is attenuation of free radical injury; however, other unknown effects of the drug cannot be completely excluded. This is the first study in the context of CPB to implicate free radicals in cerebral damage. A remarkable improvement in CBF and CMRO2 after DHCA was demonstrated with the use of PBN in the neonatal piglet. This suggests that free radical scavengers could have enormous potential as cerebral neuroprotectants in patients undergoing surgery with the use of DHCA.
| Appendix: Discussion |
|---|
|
|
|---|
Dr Langley. The main reason for not using other potentially neuroprotective strategies was that we wanted to maximize the injury caused by DHCA in the control group. You mentioned barbiturates, mannitol, and steroids, but there are a number of other mechanisms that we could also have evaluated. Dr Jonas group in Boston has looked at aprotinin and N -methyl-D -aspartate antagonists, monoclonal antibodies to CD18, and our own group has investigated the beneficial effects with thromboxane A2 antagonists and platelet activating factor antagonists. One of the problems of using a combination of strategies was determining which of the chemicals or compounds is producing the effect. We wanted to create a study that was very clear-cut, without any potentially confounding variables.
Dr Lupinetti. My second question is a little more philosophical. As we focus more carefully on brain protection, how can we avoid the unfortunate situation that currently exists in the field of myocardial protection? As you know, more than 1000 agents have been tested as possibly benefiting the ischemic heart and, remarkably enough, all of them work. This has generated numerous publications but relatively little patient benefit. I would appreciate your thoughts regarding how we might better compare competing strategies of cerebral protection and ultimately improve our clinical outcomes.
Dr Langley. That is a very interesting question and one that is difficult to answer. I am not entirely sure at the present time, however, whether an analogy between myocardial protection and cerebral protection is quite fair. Cerebral neuroprotection during cardiac surgery is fairly poorly understood. It is extremely complicated, and our comprehension of the mechanisms involved is still in its infancy. With respect to the research in the field of myocardial protection, I do not think we are talking here about adding a bit of magnesium or adding a bit of calcium to a cardioplegic solution. The current study demonstrates interruption of what is possibly the most important pathway leading to cerebral injury after ischemia. This study has demonstrated that free radicals are involved in the impairment of cerebral recovery and that a free radical scavenger, in this instance PBN, can protect the brain from free radicalmediated damage. I do not think it is necessary to investigate a whole battery of different free radical scavengers. The mechanism has been fairly convincingly demonstrated. We are eager to undertake one further animal experiment, a survival model in which we could evaluate neurobehavioral outcomes. After this, we are eager to move fairly rapidly into clinical applications of our findings.
Dr Vaughn Starnes (Los Angeles, Calif). I have two comments about how you did the study.
Do you know whether PBN has any vasodilatory effect itself? You controlled perfusion on the basis of pressure and not flow. Were the flow characteristics in the 2 groups different? In other words, did the PBN-treated group get 30% more blood flow because you were controlling pressure, not flow?
Dr Langley. We deliberately controlled CPP because it has previously been clearly demonstrated that cerebral perfusion is determined by perfusion pressure rather than by flow rate. The pump flow rate was actually significantly lower in the PBN group than in the control group.
Dr Starnes. Was there a flow difference in the 2 groups?
Dr Langley. Yes, there was. In the control group the systemic vascular resistance fell after DHCA. This fall necessitated a rise in pump flow rate to maintain the preset CPP of 50 mm Hg. In the PBN group the systemic vascular resistance was higher after DHCA and the pump flow rate was therefore reduced. The improved CBF in the PBN group can therefore not be attributed to an increase in pump flow rate.
Dr W. R. Eric Jamieson (Vancouver, British Columbia, Canada). Would you give some consideration to evaluating the two current clinical techniquesretrograde cerebral perfusion under profound hypothermia and direct arterial reperfusion under moderate hypothermiaand use the same model to assess these two current clinical parameters of management?
Dr Langley. Yes, we would. I think it would be very interesting to do that.
Dr Frank Pigula (Pittsburgh, Pa). Did you evaluate the metabolic state of the brain in any other way in terms of glucose metabolism or lactate production? Did you evaluate the potential for edema in the brain after DHCA?
Dr Langley. We did not evaluate lactate levels in this study. In the study that we presented to the Southern Thoracic Surgical Association in November 1998, which will be published in the Annals of Thoracic Surgery, we demonstrated a correlation between cerebral ultrastructure in the brain and CMRO2. We found that an abnormal CMRO2 was associated with perivascular and intracellular organelle edema and that when the CMRO2 recovered to a normal level there was a remarkable recovery in the ultrastructural findings in the brain. We believe that the normal recovery of CMRO2 in this study would be associated with a normal cerebral perivascular ultrastructural recovery.
| Acknowledgments |
|---|
| Footnotes |
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S. Schultz, D. Antoni, G. Shears, S. Markowitz, P. Pastuszko, W. Greeley, D. F. Wilson, and A. Pastuszko Brain oxygen and metabolism during circulatory arrest with intermittent brief periods of low-flow cardiopulmonary bypass in newborn piglets J. Thorac. Cardiovasc. Surg., October 1, 2006; 132(4): 839 - 844. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Schultz, J. Creed, G. Schears, T. Zaitseva, W. Greeley, D. F. Wilson, and A. Pastuszko Comparison of low-flow cardiopulmonary bypass and circulatory arrest on brain oxygen and metabolism Ann. Thorac. Surg., June 1, 2004; 77(6): 2138 - 2143. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Schears, S. E. Schultz, J. Creed, W. J. Greeley, D. F. Wilson, and A. Pastuszko Effect of perfusion flow rate on tissue oxygenation in newborn piglets during cardiopulmonary bypass Ann. Thorac. Surg., February 1, 2003; 75(2): 560 - 565. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Krishnadasan, C. R. Hampton, J. Griscavage-Ennis, R. J. Dabal, and E. D. Verrier Molecular Mechanisms of Neurologic Injury Following Cardiopulmonary Bypass Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2002; 6(1): 43 - 53. [Abstract] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |